Niina Veitonmäki

Bispecific antibodies in cancer immunotherapy

P. Norlén, E. Dahlén, N. Veitonmäki, 2018, Therapeutic advances in vaccines and immunotherapy.

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

P. Norlén, M. Lindstedt, P. Ellmark, 2014, Clinical Cancer Research.

Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb

Yihai Cao, J. Fuxe, G. Roos, 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

ANGIOSTATIC MECHANISMS OF ENDOGENOUS ANGIOGENESIS INHIBITORS

N. Veitonmäki, Niina Veitonmäki, 2003 .

Kringle structures and antiangiogenesis.

Yihai Cao, R. Cao, N. Veitonmäki, 2002, Current medicinal chemistry. Anti-cancer agents.

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

M. Johansson, P. Norlén, P. Ellmark, 2019, Journal of Immunotherapy for Cancer.

First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies

G. Ullenhag, P. Norlén, J. Yachnin, 2019, International journal of cancer.

Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

S. Kihara, T. Funahashi, Y. Matsuzawa, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates

B. Bosch, A. Lehmann, H. Binz, 2020, bioRxiv.

p130‐Angiomotin associates to actin and controls endothelial cell shape

Anindya Dutta, J. Wohlschlegel, C. Ukomadu, 2006, The FEBS journal.

Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility*

L. Holmgren, I. Sinha, A. Bratt, 2005, Journal of Biological Chemistry.